Friedreich's ataxia (FRDA) is caused by reduction of frataxin levels to 5 -35%. To better understand the biochemical sequelae of frataxin reduction, in absence of the confounding effects of neurodegeneration, we studied the gene expression profile of a mouse model expressing 25 -36% of the normal frataxin levels, and not showing a detectable phenotype or neurodegenerative features. Despite having no overt phenotype, a clear microarray gene expression phenotype was observed. This phenotype followed the known regional susceptibility in this disease, most changes occurring in the spinal cord. Additionally, gene ontology analysis identified a clear mitochondrial component, consistent with previous findings. We were able to confirm a subset of changes in fibroblast cell lines from patients. The identification of a core set of genes changing early in the FRDA pathogenesis can be a useful tool in both clarifying the disease process and in evaluating new therapeutic strategies. D
Introduction
Friedreich ataxia (FRDA), the most prevalent inherited ataxia, is most frequently caused by a GAA triplet repeat expansion within the first intron of the gene encoding for frataxin, a nuclear encoded mitochondrial protein (Campuzano et al., 1996) . The mutation affects frataxin transcription, leading to severe reduction of protein levels in homozygous patients (Bidichandani et al., 1998) . The normal function of frataxin, and how its deficiency ultimately leads to neuronal dysfunction and death, is not well understood. Deficiency of the yeast frataxin homolog protein Yfh1p causes a strong reduction in the assembly of mitochondrial proteins containing iron -sulfur clusters (ISC) (Muhlenhoff et al., 2002) , and frataxin is required for ISC assembly in yeast mitochondria (Gerber et al., 2003; Lutz et al., 2001) . These data support a specific role for frataxin in the biosynthesis of cellular ISC proteins, which may be in turn related to oxidative stress sensitivity and iron homeostasis alterations (Puccio and Koenig, 2002) .
FRDA has been a challenging disease to model in mice. Homozygous deletion of frataxin in the mouse causes embryonic lethality a few days after implantation, demonstrating a pivotal role for frataxin during early development (Cossee et al., 2000) . Heterozygous knockout mice show reduced (50%) frataxin levels, no obvious phenotype, and sporadic heart iron deposits after dietary iron load (Santos et al., 2003) . Through a conditional gene-targeting approach, neuronal, cardiac (Puccio et al., 2001) , and pancreatic (Ristow et al., 2003) frataxin knockout mice have been generated. These models show cardiac hypertrophy, large sensory neuron dysfunction, deficient ISC protein activities (Puccio et al., 2001) , and diabetes due to reactive oxygen species increase, growth arrest, and apoptosis in pancreatic beta cells (Ristow et al., 2003) .
However, in FRDA patients (Pianese et al., 2004) and in lymphoblastoid cell lines derived from FRDA patients (Campuzano et al., 1997) 
